FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine
FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozap...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozap...
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA Drug Approvals
Scope: Regulatory
Related coverage
More related coverage
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a c...
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for...
FDA adds Boxed Warning about a rare but serious allergic reaction called anaphylaxis with the multiple sclerosis medicine glatiramer acetate (Copaxone, Glatopa)
FDA adds Boxed Warning about a rare but serious allergic reaction called anaphylaxis with the multip...
FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)
FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medi...